Resultados de la búsqueda

The Global MPN Scientific Foundation is pleased to host a special webinar introducing Silence Therapeutics Date:  May 20th, 2025 Time:  6:00 PM – 7:00 PM (CEST) About Silence Therapeutics Silence Therapeutics Silence Therapeutics  collaborates globally to drive forward science  that can make a real impact on I have been in the pharmaceutical industry for 25 years helping mostly small companies like Silence Therapeutics The webinar will cover: An overview of Silence Therapeutics’ scientific approach and platform Their current

On May 20th, 2025, the Global MPN Scientific Foundation  hosted a webinar featuring Silence Therapeutics

As part of the educational collaboration between the Global MPN Scientific Foundation  and Silence Therapeutics This third session of the webinar series brings together experts from Silence Therapeutics who will share Curtis Rambaran, Chief Medical Officer, Silence Therapeutics 🎤 Speaker:  Joe Loiars, Senior Director Medical Science Liaison, Silence Therapeutics USA 🤝 Organized by:  Global MPN Scientific Foundation Curtis Rambaran  will introduce the structure and research strategy of Silence Therapeutics and explain

Therapeutics , a biotech company developing precision RNA-based therapies for rare diseases such as Alberto Martinez , Senior Director of Clinical Science at Silence Therapeutics. Content guide Part 1: Silence Therapeutics and a Promising New Treatment for PV Watch More on MPN World Part 1: Silence Therapeutics and a Promising New Treatment for PV In the first part, Alberto Martinez Therapeutics is advancing innovative approaches that could help reduce phlebotomies and improve quality

This webinar explores the divesiran clinical trial , developed by Silence Therapeutics , and provides reliable information can help patients, caregivers, and healthcare professionals better understand how new therapeutic In this webinar, experts from Silence Therapeutics present key aspects of the divesiran clinical trial to expanding knowledge about polycythemia vera and help researchers better understand how different therapeutic

Following the success of our first webinar with Silence Therapeutics , we are excited to announce the This time, we continue on Silence Therapeutics and their investigational therapy for Polycythemia Vera About Silence Therapeutics Webinar Details Register now What to Expect? Alberto Martinez ( Senior Director of Clinical Science at Silence Therapeutics )He will continue explaining About Silence Therapeutics Silence Therapeutics  is a UK-based biotech company developing precision RNA-based

ongoing research in polycythemia vera (PV) , with a focus on the divesiran clinical trial  developed by Silence Therapeutics . This session offers an accessible overview of innovative therapeutic approaches  currently being studied Comprehensive Cancer Center  (United States), shares key updates on the trial, including its design , therapeutic

We also hosted and supported webinars on ongoing clinical trials , including sessions with: Silence Therapeutics

Takeda and Protagonist Therapeutics, Inc. , today announced the signing of a worldwide license and collaboration Patel, Ph.D., President and CEO of Protagonist Therapeutics .

The first presentation was given by Alberto Martínez , Senior Director of Clinical Science at Silence Therapeutics , who shared insights on RNA based approaches  in MPNs and how patient-reported outcomes

But you don't have to suffer in silence. But you don't have to suffer in silence.

Verstovsek, world-leading MPN researcher The Global MPN Scientific Foundation, in collaboration with Kartos Therapeutics Content Guide PART 1 – A New Era: Navtemadlin and the Therapeutic Approach Want to watch Parts 2 and Why this matters PART 1 – A New Era: Navtemadlin and the Therapeutic Approach Dr.